GLOBUS MEDICAL INC insider trading
GMEDfinancial statementsForm 4 filings on EDGAR53 transactions since Nov 9, 2024
From August 12, 2026 to November 9, 2026, 0 insiders at GLOBUS MEDICAL INC bought $0 of stock in the open market, and 3 sold $5M. Officers and directors accounted for $0 of purchases and $5M of sales. The last reported transaction was an open-market sale by Rhoads Ann D on November 4, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through November 5, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $5MAug 12, 2026 – Nov 9, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Nov 6, 2026. Insider data through Nov 9, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
53 transactions from November 9, 2024 to November 9, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Rhoads Ann D | Director | open-market sale10b5-1 | 5,000 | $85.00 | $425K | 35,384 | Nov 5, 2026 |
| Sep 15, 2026 | Tobin James R | Director | option exercise | 15,000 | $53.75 | $806K | 15,000 | Sep 16, 2026 |
| Sep 15, 2026 | Tobin James R | Director | option exercise | 15,000 | $63.68 | $955K | 30,000 | Sep 16, 2026 |
| Sep 15, 2026 | Tobin James R | Director | open-market sale | 30,000 | $74.58 | $2M | 0 | Sep 16, 2026 |
| Aug 18, 2026 | Zarrilli Stephen T | Director | option exercise | 25,000 | $53.27 | $1M | 25,000 | Aug 19, 2026 |
| Aug 18, 2026 | Zarrilli Stephen T | Director | open-market sale | 25,000 | $87.04 | $2M | 0 | Aug 19, 2026 |
| Jul 27, 2026 | Davidar David D | Director | gift | 2,500 | $0.00 | — | 507,675 | Jul 28, 2026 |
| Jun 5, 2026 | Davidar David D | Director | option exercise | 25,000 | $26.27 | $657K | 535,175 | Jun 9, 2026 |
| Jun 5, 2026 | Davidar David D | Director | open-market sale | 25,000 | $80.76 | $2M | 510,175 | Jun 9, 2026 |
| Jun 4, 2026 | Rhoads Ann D | Director | option exercise | 25,000 | $26.27 | $657K | 40,384 | Jun 8, 2026 |
| Feb 25, 2026 | Huller Kelly | EVP, GC, Corporate Secretary | option exercise | 20,000 | $43.58 | $872K | 20,000 | Feb 27, 2026 |
| Feb 25, 2026 | Huller Kelly | EVP, GC, Corporate Secretary | open-market sale10b5-1 | 20,000 | $94.50 | $2M | 0 | Feb 27, 2026 |
| Feb 12, 2026 | Huller Kelly | EVP, GC, Corporate Secretary | option exercise | 10,000 | $45.64 | $456K | 10,000 | Feb 17, 2026 |
| Feb 12, 2026 | Huller Kelly | EVP, GC, Corporate Secretary | open-market sale10b5-1 | 10,000 | $87.67 | $877K | 0 | Feb 17, 2026 |
| Jan 8, 2026 | Kline Kyle | Senior Vice President, CFO | option exercise | 3,594 | $51.87 | $186K | 3,594 | Jan 12, 2026 |
| Jan 8, 2026 | Kline Kyle | Senior Vice President, CFO | open-market sale10b5-1 | 3,594 | $101.10 | $363K | 0 | Jan 12, 2026 |
| Jan 8, 2026 | Norwalk Leslie V | Director | open-market sale10b5-1 | 2,000 | $101.10 | $202K | 10,419 | Jan 12, 2026 |
| Dec 12, 2025 | Norwalk Leslie V | Director | open-market sale10b5-1 | 4,000 | $88.85 | $355K | 12,419 | Dec 16, 2025 |
| Dec 8, 2025 | Paul David C | Executive Chairman, Director, 10% owner | option exercise | 34,375 | $25.52 | $877K | 60,417 | Dec 10, 2025 |
| Dec 1, 2025 | Kline Kyle | Senior Vice President, CFO | option exercise | 3,646 | $53.14 | $194K | 3,646 | Dec 3, 2025 |
| Dec 1, 2025 | Kline Kyle | Senior Vice President, CFO | option exercise | 5,000 | $56.43 | $282K | 8,646 | Dec 3, 2025 |
| Dec 1, 2025 | Kline Kyle | Senior Vice President, CFO | option exercise | 5,000 | $64.44 | $322K | 13,646 | Dec 3, 2025 |
| Dec 1, 2025 | Kline Kyle | Senior Vice President, CFO | option exercise | 4,896 | $63.68 | $312K | 18,542 | Dec 3, 2025 |
| Dec 1, 2025 | Kline Kyle | Senior Vice President, CFO | open-market sale10b5-1 | 18,542 | $90.00 | $2M | 0 | Dec 3, 2025 |
| Nov 25, 2025 | Huller Kelly | SVP, GC, Corporate Secretary | open-market sale10b5-1 | 7,500 | $90.00 | $675K | 0 | Nov 28, 2025 |
| Nov 25, 2025 | Huller Kelly | SVP, GC, Corporate Secretary | option exercise | 7,500 | $25.96 | $195K | 7,500 | Nov 28, 2025 |
| Nov 12, 2025 | Davidar David D | Director | option exercise | 25,000 | $25.52 | $638K | 541,275 | Nov 13, 2025 |
| Nov 12, 2025 | Davidar David D | Director | open-market sale | 25,000 | $86.00 | $2M | 516,275 | Nov 13, 2025 |
| Nov 11, 2025 | Zarrilli Stephen T | Director | option exercise | 25,000 | $44.14 | $1M | 25,000 | Nov 13, 2025 |
| Nov 11, 2025 | Zarrilli Stephen T | Director | open-market sale | 25,000 | $84.29 | $2M | 0 | Nov 13, 2025 |
| Nov 10, 2025 | Rhoads Ann D | Director | open-market sale10b5-1 | 2,000 | $85.00 | $170K | 15,384 | Nov 10, 2025 |
| Nov 7, 2025 | Rhoads Ann D | Director | open-market sale10b5-1 | 8,000 | $81.00 | $648K | 17,384 | Nov 10, 2025 |
| Sep 15, 2025 | Rhoads Ann D | Director | open-market sale10b5-1 | 10,000 | $58.46 | $585K | 25,384 | Sep 16, 2025 |
| Feb 28, 2025 | Rhoads Ann D | Director | open-market sale10b5-1 | 7,500 | $78.68 | $590K | 35,384 | Mar 4, 2025 |
| Jan 10, 2025 | Pfeil Keith W | COO, CFO | option exercise | 8,334 | $53.27 | $444K | 14,167 | Jan 14, 2025 |
| Jan 10, 2025 | Pfeil Keith W | COO, CFO | open-market sale10b5-1 | 1,666 | $89.17 | $149K | 0 | Jan 14, 2025 |
| Jan 10, 2025 | Pfeil Keith W | COO, CFO | open-market sale10b5-1 | 12,501 | $88.17 | $1M | 1,666 | Jan 14, 2025 |
| Jan 10, 2025 | Pfeil Keith W | COO, CFO | option exercise | 5,833 | $49.65 | $290K | 5,833 | Jan 14, 2025 |
| Jan 2, 2025 | Davidar David D | Director | gift | 6,100 | $0.00 | — | 510,175 | Jan 5, 2026 |
| Dec 2, 2024 | Huller Kelly | SVP, GC, Corporate Secretary | open-market sale10b5-1 | 2,500 | $87.00 | $218K | 0 | Dec 4, 2024 |
| Dec 2, 2024 | Huller Kelly | SVP, GC, Corporate Secretary | option exercise | 2,500 | $24.21 | $61K | 2,500 | Dec 4, 2024 |
| Nov 22, 2024 | Davidar David D | Director | open-market sale10b5-1indirect | 6,746 | $85.00 | $573K | 165,967 | Nov 25, 2024 |
| Nov 22, 2024 | Davidar David D | Director | open-market sale10b5-1 | 6,766 | $85.00 | $575K | 516,275 | Nov 25, 2024 |
| Nov 22, 2024 | Lemaitre Dan | Director | open-market sale | 1,097 | $85.02 | $93K | 0 | Nov 25, 2024 |
| Nov 22, 2024 | Lemaitre Dan | Director | option exercise | 1,097 | $65.05 | $71K | 1,097 | Nov 25, 2024 |
| Nov 21, 2024 | Davidar David D | Director | open-market sale10b5-1indirect | 13,254 | $85.00 | $1M | 172,713 | Nov 25, 2024 |
| Nov 21, 2024 | Davidar David D | Director | open-market sale10b5-1 | 13,234 | $85.00 | $1M | 523,041 | Nov 25, 2024 |
| Nov 21, 2024 | Lemaitre Dan | Director | option exercise | 13,278 | $65.05 | $864K | 13,278 | Nov 25, 2024 |
| Nov 21, 2024 | Lemaitre Dan | Director | open-market sale | 13,278 | $85.00 | $1M | 0 | Nov 25, 2024 |
| Nov 21, 2024 | Scavilla Daniel T | President, CEO, Director | option exercise | 50,000 | $43.77 | $2M | 50,000 | Nov 25, 2024 |
Who the insiders are
Everyone who reported a transaction since November 9, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Zarrilli Stephen T | Director | Aug 18, 2026 | option exercise | 25,000 | — | $4M (2) | 0 of 2 |
| Davidar David D | Director | Jul 27, 2026 | gift | 507,675 | — | $4M (2) | 0 of 2 |
| Huller Kelly | EVP, GC, Corporate Secretary | Feb 25, 2026 | option exercise | 20,000 | — | $3M (3) | 3 of 3 |
| Tobin James R | Director | Sep 15, 2026 | option exercise | 15,000 | — | $2M (1) | 0 of 1 |
| Kline Kyle | Senior Vice President, CFO | Jan 8, 2026 | option exercise | 3,594 | — | $2M (2) | 2 of 2 |
| Rhoads Ann D | Director | Nov 4, 2026 | open-market sale | 35,384 | — | $595K (2) | 2 of 2 |
| Norwalk Leslie V | Director | Jan 8, 2026 | open-market sale | 10,419 | — | $558K (2) | 2 of 2 |
| Pfeil Keith W | COO, CFO | Jan 10, 2025 | option exercise | 14,167 | — | — | — |
| Lemaitre Dan | Director | Nov 22, 2024 | open-market sale | 0 | — | — | — |
| Scavilla Daniel T | President, CEO, Director | Nov 21, 2024 | option exercise | 50,000 | — | — | — |
| Paul David C | Executive Chairman, Director, 10% owner | Dec 8, 2025 | option exercise | 60,417 | — | — | — |
Questions
Are GLOBUS MEDICAL INC insiders buying or selling?
Over the twelve months to November 9, 2026, 7 insiders at GLOBUS MEDICAL INC sold $17M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $17M. Only open-market purchases and sales are counted.
Who sold the most GLOBUS MEDICAL INC stock in the last year?
Zarrilli Stephen T (Director) sold $4M in 2 open-market sales over the twelve months to November 9, 2026.
Do GLOBUS MEDICAL INC executives sell under 10b5-1 plans?
9 of the 14 open-market sales in the last twelve months (64%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on GLOBUS MEDICAL INC
- GLOBUS MEDICAL INC financial statements
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.